The present invention relates to a compound or a pharmacologically acceptable salt thereof that has an excellent antagonistic effect on a neurokinin NK1 receptor, a neurokinin NK2 receptor, and a muscarine M3 receptor and is useful as a therapeutic agent for bronchial asthma, chronic obstructive pulmonary disease, or the like.A compound represented by general formula (I):[whereinR1 represents a hydrogen atom, a C1-C6 alkyl group, or the like R2 represents a hydrogen atom, a C1-C6 alkyl group, or the like R3 represents a phenyl group that may be substituted with 1 to 5 group(s) independently selected from Substituent Group A, or the like R4 represents a phenyl group that may be substituted with 1 to 5 group(s) independently selected from Substituent Group A, or the like L1 represents a C1-C10 alkylene group or the like L2 represents a carbonyl group, a group represneted by the formula -N(R5)-C(=O)-, a group represented by the formula -C(=O)-N(R5)-, or the like R5 represents a hydrogen atom, a C1-C6 alkyl group, or the like E represents a phenylene group that may be substituted with 1 to 4 group(s) independently selected from Substituent Group A, or the like m is an integer of 1 to 4 n is an integer of 0 to 4 p is an integer of 0 to 2 q is an integer of 1 to 10 r is 1 or 2 s is 0 or 1 and Substituent Group A represents the group consisting of a halogen atom, a C1-C6 alkyl group, C1-C6 halogenated alkyl group, or the like] or a pharmacologically acceptable salt thereof.
